Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro
Alnylam's (ALNY) label expansion-seeking application for Onpattro, to treat transthyretin-mediated amyloidosis with cardiomyopathy, gets the FDA's CRL on the grounds of insufficient data. The stock...
Top stocks October 9, 2023: Tesla, Bristol Myers-Mirati, Alnylam Pharma
Tesla (TSLA) shares are in focus as China-made EV demand drops by 10%, affecting Model 3 and Y sales. Tesla's delivery and production data declined from last quarter following a report by the China...
Alnylam Stock Is Dropping on Surprising FDA Rejection
Drugmaker Alnylam wanted to expand approval of its drug Onpattro, but the Food and Drug Administration rejected the application even after an outside advisory committee voted in favor of it.
US FDA declines approval for expanded use of Alnylam's heart-disease drug
The U.S. Food and Drug Administration has declined to approve the expanded use of Alnylam Pharmaceuticals' drug to treat a rare and fatal heart disease, citing insufficient evidence of clinical mea...
Alnylam to scrap sNDA for patisiran after receiving FDA complete response letter
Alnylam Pharmaceuticals Inc. ALNY, -1.00% said Monday it would no longer pursue its supplemental new drug application (sNDA) for patisiran as a treatment for the cardiomyopathy of transthyretin-med...
2 Growth Stocks That Could Rocket Higher Before the End of 2023
Upcoming announcements from the U.S. Food and Drug Administration could cause several biotech stocks to rocket higher. Alnylam is expecting a decision regarding a progressive heart condition that c...
Alnylam's (ALNY) Onpattro sNDA Gets FDA Advisory Committee Nod
Alnylam (ALNY) receives a positive opinion from the FDA's advisory committee regarding the label expansion of patisiran to treat the cardiomyopathy of transthyretin-mediated amyloidosis.
U.S. FDA panel backs expanded use of Alnylam's gene silencing drug
An outside panel of experts to the U.S. Food and Drug Administration on Wednesday backed the expanded use of Alnylam Pharmaceuticals' gene silencing drug to treat a type of heart disease associated...
Buy List Alert: 3 Pharma Stocks with Positive Trial Updates
The pharmaceutical industry is one of the most dynamic and innovative sectors in the world. It is constantly developing new drugs and treatments to address various health challenges and improve the...
Alnylam Pharmaceuticals' stock to be halted Wednesday as FDA advisory panel reviews treatment for the Cardiomyopathy of ATTR Amyloidosis
Alnylam Pharmaceuticals Inc. ALNY, +3.89% said Wednesday its stock will be halted on Nasdaq through the day as a regulatory advisory committee will meet to review its new drug application for a tre...
Alnylam Continues To Deliver, But An Upcoming FDA Meeting Could Create Some Volatility
Alnylam has an upcoming FDA advisory committee meeting on the company's application for Onpattro in ATTR-CM, and I see some risk of a negative committee vote. Onpattro has met or exceeded the effic...
Alnylam's (ALNY) Zilebesiran Meets Goals in Mid-Stage Study
Alnylam's (ALNY) mid-stage study of zilebesiran in the treatment of hypertension in patients at high cardiovascular risk meets primary and key secondary endpoints.
Alnylam hypertension drug meets main goal in mid-stage study
Alnylam Pharmaceuticals said on Thursday its experimental therapy for hypertension met the main goal in a mid-stage study.
Alnylam to appeal ruling on patents related to Moderna's COVID vaccines
Alnylam Pharmaceuticals said on Friday it plans to appeal a ruling by the U.S. District Court for the District of Delaware on two patents asserted against Moderna for the latter's COVID-19 vaccine ...
Related Companies